Related Experiment Video

Updated: Jan 10, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.8K

Efficacy and Safety of the Individual Batroxobin Strategy in Treating Cerebral Venous Thrombosis: An Obstervational

Duo Lan1,2, Xiangqian Huang1,2, Xiaoming Zhang1,2

  • 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|November 26, 2025
PubMed

Insights

Individualized batroxobin treatment significantly improved recanalization rates and reduced stenosis in cerebral venous thrombosis (CVT) patients compared to standard protocols. This approach showed enhanced efficacy without increasing bleeding risks.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Pharmacology

Background:

  • Cerebral venous thrombosis (CVT) treatment benefits from batroxobin, but optimal strategies require further investigation.
  • Maximizing clinical effectiveness of batroxobin for CVT correction is crucial for patient outcomes.
  • This study addresses the need for optimized batroxobin application in acute CVT management.

Purpose of the Study:

  • To evaluate the efficacy and safety of individualized batroxobin treatment strategies for acute cerebral venous thrombosis (CVT).
  • To compare recanalization rates and stenosis attenuation between individualized and standard batroxobin protocols in CVT patients.

Main Methods:

  • An observational clinical study involving 41 patients with acute CVT.
  • Patients were categorized into an individualized group (batroxobin >5 times) and a standard group (batroxobin 3 times).
  • Magnetic Resonance Blood-sensitive Imaging (MRBTI) assessed recanalization and stenosis; bleeding events were monitored.

Main Results:

  • The individualized batroxobin group demonstrated significantly higher recanalization rates (14/16) compared to the standard group (17/25).
  • Greater attenuation of segmental stenosis was observed in the individualized treatment group.
  • No significant difference in bleeding event incidence was found between the two treatment strategies.

Conclusions:

  • Individualized batroxobin strategies appear more effective than standard protocols for improving CVT recanalization and reducing stenosis.
  • The findings suggest potential benefits of tailored batroxobin dosing for managing cerebral venous thrombosis.
  • Further clinical trials are warranted to confirm the efficacy of this individualized therapeutic approach.

Keywords:
anticoagulationbatroxobincerebral venous thrombosisindividualthrombolysis

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.3K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
277
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
188